690 related articles for article (PubMed ID: 34745121)
1. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
2. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
Zhao K; Zhang Q; Flanagan SA; Lang X; Jiang L; Parsels LA; Parsels JD; Zou W; Lawrence TS; Buisson R; Green MD; Morgan MA
Mol Cancer Res; 2021 Sep; 19(9):1571-1582. PubMed ID: 34045311
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer.
Xu F; Zou C; Gao Y; Shen J; Liu T; He Q; Li S; Xu S
Front Immunol; 2022; 13():930488. PubMed ID: 36091054
[TBL] [Abstract][Full Text] [Related]
4. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
5. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
6. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
8. Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.
Tian W; Shan B; Zhang Y; Ren Y; Liang S; Zhao J; Zhao Z; Wang G; Zhao X; Peng D; Bi R; Cai S; Bai Y; Wang H
Cancer Med; 2020 Mar; 9(6):2190-2200. PubMed ID: 31991061
[TBL] [Abstract][Full Text] [Related]
9. Identification of immune microenvironment subtypes that predicted the prognosis of patients with ovarian cancer.
Wang X; Li X; Wang X
J Cell Mol Med; 2021 Apr; 25(8):4053-4061. PubMed ID: 33675171
[TBL] [Abstract][Full Text] [Related]
10. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
11. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
12. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.
Liu T; Shen J; He Q; Xu S
Front Genet; 2022; 13():814291. PubMed ID: 35237300
[TBL] [Abstract][Full Text] [Related]
14. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z
Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981
[TBL] [Abstract][Full Text] [Related]
15. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
16. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
18. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients.
Liu J; Wang Y; Yuan S; Wei J; Bai J
Front Immunol; 2021; 12():751594. PubMed ID: 34745124
[TBL] [Abstract][Full Text] [Related]
19. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
20. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]